Cyclin D1 expression in acral melanoma: a case control study in Sarawak.

Malays J Pathol

Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kuching, Malaysia.

Published: December 2012

Acral melanoma has been reported to have distinctive clinical presentation and ethnic distribution compared to other histological types of malignant melanoma. Acral melanoma also exhibits distinctive focused gene amplifications, including cyclin D1 overexpression. We reviewed archived histological material of malignant melanoma in the Sarawak General Hospital from year 2004 to 2010. 43 tumours, comprising 28 acral melanoma and 15 non-acral melanoma, had sufficient material to be included in the study. The majority (36%) of acral melanoma tumours occurred in the heel. The tumours were analyzed for cyclin D1 expression by immunohistochemistry. 68% of acral melanoma were cyclin D1 positive compared to a positivity of 33% in non-acral tumours. This difference was statistically significant (p < 0.05). This finding may improve the histological diagnosis of acral melanoma and detection of positive resection margins.

Download full-text PDF

Source

Publication Analysis

Top Keywords

acral melanoma
28
melanoma
10
cyclin expression
8
malignant melanoma
8
acral
7
cyclin
4
expression acral
4
melanoma case
4
case control
4
control study
4

Similar Publications

Background: Digital papillary adenocarcinoma (DPAC) is a rare but aggressive cutaneous malignant sweat gland neoplasm that occurs on acral sites. Despite its clinical significance, the cellular and genetic characteristics of DPAC remain incompletely understood.

Methods: We conducted a comprehensive genomic and transcriptomic analysis of DPAC (n = 14) using targeted next-generation DNA and RNA sequencing, along with gene expression profiling employing the Nanostring Technologies nCounter IO 360 Panel.

View Article and Find Full Text PDF

Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. We sought to determine the objective response rate of combination durvalumab (D) plus tremelimumab (TM) in parallel cohorts of patients with carefully selected rare cancer types in which these agents had not previously been evaluated in phase II trials and for which there was clinical or biological rationale for dual immune checkpoint inhibitor therapy to be active.

Methods: We designed a multi-centre, non-blinded, open-label phase II basket trial with each of the following 8 rare cancers considered a separate phase II trial: salivary carcinoma, carcinoma of unknown primary (CUP) with tumour infiltrating lymphocytes and/or expressing PD-L1, mucosal melanoma, acral melanoma, osteosarcoma, undifferentiated pleomorphic sarcoma, clear cell carcinoma of the ovary (CCCO) or squamous cell carcinoma of the anal canal (SCCA).

View Article and Find Full Text PDF

Major underlying health issues can be indicated by even minor nail infections. Subungual Melanoma is one of the most severe kinds since it is identified at a much later stage than other conditions. The purpose of this research is to offer novel deep-learning algorithms that target the autonomous categorization of six forms of nail disorders by employing images: Blue Finger, Clubbing, Pitting, Onychogryphosis, Acral Lentiginous Melanoma, and Normal Nail or Healthy Nail Appearance.

View Article and Find Full Text PDF

Background: Isolated immunohistochemical indicators are limited to diagnose melanocytic neoplasms. This retrospective study is to assess the diagnostic value of combined immunohistochemical analysis targeting preferentially expressed antigen in melanoma (PRAME) and p16 in melanocytic neoplasms, with a detailed focus on arcal lesions.

Methods: This was a single center cohort study from January 2022 to June 2023.

View Article and Find Full Text PDF

Three-Dimensional Nuclear Architecture and Genomic Structural Variations in Melanoma.

J Invest Dermatol

December 2024

Department of Dermatology, Cleveland Clinic, Cleveland, OH, USA; Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!